A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)

NCT01678820 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

299

Enrollment

INDUSTRY

Sponsor class

Stopped Merck terminated the study for business reasons in November 2013.

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Sitagliptin/Simvastatin FDC
DRUG: Sitagliptin
DRUG: Simvastatin
DRUG: Placebo to sitagliptin
DRUG: Placebo to simvastatin
DRUG: Placebo to Sitagliptin/Simvastatin FDC
DRUG: Metformin
DRUG: Glimepiride

Sponsor

Merck Sharp & Dohme LLC